The first quarter of 2012 is in the books, and it looks like Boston is settling into some typical spring weather. Time to look back on our editor’s picks for top stories of Q1.
As usual, these are not necessarily the highest-traffic stories, though in some cases they are. They are the stories that exemplify the reporting, writing, and editing that we do day in and day out as we cover important events in the business of technology and life sciences. And they serve to remind us of what kinds of pieces stand the test of time—and stand out from the pack.
Our first-quarter picks span a range of profiles (CloudBees) and innovation cluster stories (fashion tech), deals (Celgene-Avila) and analysis (Google-ITA), and startups (Intrepid Labs, Satori) and big companies (Hewlett-Packard, Biogen Idec, Sanofi) alike. Then, just to mix things up, we threw in some interesting opining from local tech and life sciences leaders (Nabeel Hyatt, Rob May, Mark Levin).
Without further ado, here are our editor’s picks for top technology and life sciences stories…
Top 10 Tech Stories:
Don’t Read Tech Blogs: 10 Ideas from Backupify’s Rob May
ITA Software Emerges from Google’s Shadow with New Airline Platform
How to Disrupt IBM, Oracle, and VMware: The CloudBees Story
Fashion Tech Startups Emerging from Harvard Business School Runway in Droves: The (Fashion) Slide Show
Nabeel Hyatt on the Next Consumer Startup Model: Metrics + Creative
Assholicism: Do CEOs Need to Be Jerks to Be Successful?
Intrepid Labs: Boston’s Newest Co-Working Spot for Maturing Startups
Hewlett-Packard Expands to Cambridge via Vertica’s “Big Data” Center
OpenView Labs Aims to Prime Portfolio Companies for Big Growth
Safari Books Buys Threepress, Forges Ahead in Digital Publishing Jungle
Top 10 Life Sciences Stories:
Third Rock’s Mark Levin: “Ultra-Super Positive” on Biotech Innovation
Satori Cultivates Prolific Herb for Promising Alzheimer’s Weapon
Why Biogen Idec Got Out of the Corporate VC Business
Family Affair: Courtagen Applies Management DNA to Genomics Startup
Transparency Launches as Linux of Drug Development
Celgene Buys Avila for $350M, Gaining Promising “Covalent” Drugs
Vertex Vows to Fight On With Alios Drugs in High-Stakes Hepatitis C Race
Sanofi CEO Viehbacher on Stirring Innovation in the Era of R&D Cutbacks
Par8o, from Sermo Founders, Aims to Be Patient-Physician Matchmakers
Inspiration Bio Founders and Execs Inspired by New Boston Headquarters